Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKesson
Colorcon
Medtronic
Baxter

Last Updated: February 9, 2023

Details for Patent: 7,560,122


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,560,122
Title:Pharmaceutical dosage form bearing pregnancy-friendly indicia
Abstract: A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of erroneous dispensing of or erroneous ingestion of pharmaceutical dosage forms not intended for pregnant women. Also disclosed is a method for achieving improved patient compliance resulting in improved product effectiveness. Also disclosed is a method for diminishing the incidence of erroneous dispensing of or erroneous ingestion of dosage forms not intended for pregnant women. Said methods comprising providing a pharmaceutical dosage form, intended for use by pregnant women, bearing pregnancy-friendly indicia apt to graphically distinguish dosage forms intended to be used during pregnancy from others.
Inventor(s): Gervais; Eric (Laval, CA), Atanackovic; Gordana (Dollard-des-Ormeaux, CA), Hebert; Raymond (Ile Bizard, CA)
Assignee: Duchesnay Inc. (Laval, Quebec, CA)
Application Number:10/611,803
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,560,122
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 7,560,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,560,122

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Canada2392486Jul 05, 2002

International Family Members for US Patent 7,560,122

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003245774 See Plans and Pricing
Belgium 1016043 See Plans and Pricing
Canada 2392486 See Plans and Pricing
France 2841783 See Plans and Pricing
Greece 1004641 See Plans and Pricing
Greece 20030100286 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Express Scripts
Baxter
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.